multiple cancers
Oncology · 2020–2022
2decisions
2medicines
0carried consumer input
0individual submissions
No submission for this condition has carried consumer input, including the 2 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| pembrolizumab Addition of 400 mg every six weeks dosing regimen for pembrolizumab for treatment of urothelial cancer, colorectal cancer, primary mediastinal B-cell lymphoma,… | Jul 2022 | Recommended | none received |
| bevacizumab Biosimilar bevacizumab for five indications: metastatic colorectal cancer, advanced/metastatic/recurrent non-squamous NSCLC, relapsed/recurrent glioblastoma,… | Jul 2020 | Recommended with restriction | none received |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.